The first narcotic drug specifically designed to combat postnatal depression was approved by the US Food and Drug Administration (FDA) on Tuesday.
Zulresso, created by Sage Therapeutics, is a IV drug "as a continuous infusion" for 60 hours or two and a half days, the agency said in a press release. study of new mothers with moderate or severe postpartum depression reportedly reported that half of Zulresso-treated women had an end to depression within two and a half days ̵
But some other mothers experience stronger, heavier emotions that are considered postnatal depression. Excessive fatigue, difficulty connecting with a newborn child, fear of an inadequate mother, or total hopelessness are symptoms associated with postpartum depression that, according to medical staff, may develop during the first few weeks after birth but may begin sooner or later . affects about 400,000 American women a year and can be treated with antidepressants that can take six to eight weeks to work and not help everyone or with counseling. "Post-natal depression is a serious condition that can be life-threatening in severe cases," Dr. Tiffany Farhony of the FDA's Psychiatric Department said Farchionne added that postnatal depression can also interfere with maternal and infant attachment. is the first time that the drug is specifically approved for the treatment of postnatal depression, which is an important new therapeutic option. "Sage Chief Executive Dr. Jeff Jans says the infusion helps restore norm (19659005) The company – which develops similar treatment in pills – plans
The company – which develops similar treatment in pills – plans
Associated Press contributed to this report